Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bn

pharmaceutical-technologyNovember 15, 2018

Tag: AstraZeneca , Sobi , Synagis drug , palivizumab

PharmaSources Customer Service